Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of guselkumab in pediatric Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis
CTR20250192Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of guselkumab in Crohn's disease, autoimmune colitis and juvenile psoriatic arthritis (JPsA), sponsored by Janssen Pharmaceutical. Primary endpoints: Incidence of adverse events (AEs), Incidence of serious adverse events (SAEs) and 3 more. Started Mar 2025; status: active.
02
Drugs
guselkumab
03
Conditions
Crohn's diseaseautoimmune colitisjuvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on CTR20250192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250192.